## SUPPLEMENTARY MATERIAL

## Discovery of novel West Nile Virus protease inhibitor based on isobenzonafuranone and triazolic derivatives of eugenol and indan-1,3dione scaffolds

André S. de Oliveira <sup>1,2¶</sup>, Poliana Aparecida Rodrigues Gazolla<sup>2¶</sup>, Ana Flávia C. da S. Oliveira<sup>1,2¶</sup>, Wagner Luiz Pereira<sup>2</sup>, Lívia Cristina de Souza Viol<sup>2</sup>, Angélica Faleiros da Silva Maia<sup>2</sup>, Edjon G. Santos<sup>1</sup>, Ítalo Esposti P. da Silva<sup>1</sup>, Tiago Antônio de Oliveira Mendes<sup>4</sup>, Adalberto Manoel da Silva<sup>3</sup>, Roberto Sousa Dias<sup>1</sup>, Cynthia Canedo da Silva<sup>1</sup>, Marcelo D. Polêto<sup>1</sup>, Róbson R. Teixeira<sup>3\*</sup>, and Sergio O. de Paula<sup>\*1</sup>

<sup>1</sup> Departamento de Biologia Geral, Universidade Federal de Viçosa, Av. P.H. Rolfs, S/N, Viçosa-MG (Brazil).

<sup>2</sup> Instituto Federal de Educação, Ciência e Tecnologia do Norte de Minas Gerais, Fazenda Biribiri, S/N, Diamantina-MG (Brazil).

<sup>3</sup> Departamento de Química, Universidade Federal de Viçosa, Av. P.H. Rolfs, S/N, Viçosa-MG (Brazil).

<sup>4</sup> Departamento de Bioquímica Biologia Molecular, Universidade Federal de Viçosa, Av. P.H. Rolfs, S/N, Viçosa-MG (Brazil).

<sup>5</sup> Instituto Federal de Educação, Ciência e Tecnologia Catarinense, Campus Araquari Rodovia BR 280, km 27 - Araquari-SC (Brazil).

\* Corresponding authors depaula@ufv.br (SOP) robsonr.teixeira@ufv.br (RRT) <sup>¶</sup>These authors contributed equally.

## CONTENTS

Page

Table A	. 3
Selected IR AND NMR SPECTRA	. 12
Figure S1	73

		Table A: Docking of the compounds 23	3 to 49 with	WNV pro	tease
Comp.	Ligation type	Ligation Description	Interacti on distance (Å)	аа	Docking/Ligation Energy
23	Hydrogen Bond	OH of the amino acid with the oxygen of the carbonic chain of the molecule	2,45	Thr <sup>132</sup>	EnergyEnergy: -2,318
24		No chemical interaction predicted			Energy: -1,081
25	Hydrogen Bond	NH2 of the amino acid with the oxygen of the carbonic chain of the molecule	1,92	Asn <sup>84</sup>	
25	Halogen Bond	OH of the amino acid with the chlorine of the molecule	3,26	Thr <sup>134</sup>	Le Sta
25	Halogen Bond	NH⁺ of the amino acid with the iodine of the molecule	2,62	Gly <sup>133</sup>	1000
25	Halogen Bond	NH⁺ of the amino acid with the iodine of the molecule	3,42	Thr <sup>134</sup>	Energy: +2.058
25	cation-π	NH⁺ of the amino acid ring with the phenyl ring of the molecule	6,39	His <sup>51</sup>	0, /
25	π-π stacking	Amino acid ringwith the triazole ring of the molecule	4,11	His <sup>51</sup>	

Table A: Docking of the compounds 23 to 49 with WNV protease						
Comp.	Ligation type	Ligation Description	Interacti on distance (Å)	aa	Docking/Ligation Energy	
26		No chemical interaction predicted			Energy: -0,429	
27	cation-π	NH <sup>+</sup> of the amino acid ring with the triazole ring of the molecule	5,43	His <sup>51</sup>		
27	cation-π	NH⁺ of the amino acid ring with the phenyl ring of the molecule	6,20	His <sup>51</sup>	STAR.	
27	π-π stacking	Amino acid ringwith the phenyl ring of the molecule	5,15	His <sup>51</sup>	A A A A A A A A A A A A A A A A A A A	
27	Halogen Bond	NH <sup>+</sup> of the amino acid with the iodine of the molecule	2,43	Ser <sup>135</sup>	Energy: -0,055	
27	Halogen Bond	NH <sup>+</sup> of the amino acid with the iodine of the molecule	2,82	Thr <sup>134</sup>		
28	Hydrogen Bond	OH of the amino acid with the oxygen of the carbonic chain of the molecule	2,24	Thr <sup>132</sup>		
28	Hydrogen Bond	$O^{-}$ of the amino acid with the NO <sub>2</sub> H <sub>2</sub> of the molecule	1,89	Asp <sup>12</sup> 9	Se Sta	
28	Hydrogen Bond	$O^{-}$ of the amino acid with the NO <sub>2</sub> H <sub>2</sub> of the molecule	2,07	Asp <sup>12</sup> 9	1500 B	
28	Hydrogen Bond	NH⁺ of the amino acid with the nitrogen of triazole ring of the molecule	2,46	Ser <sup>135</sup>	Energy: -2,732	
28	π-π stacking	Amino acid ring with the phenyl ring of the molecule	4,39	Tyr <sup>161</sup>		
29	Hydrogen Bond	NH <sup>+</sup> of the amino acid wit the OCH₃ of the phenyl ring in the molecule	1,98	Gly <sup>133</sup>	OPA DE	

		Table A: Docking of the compounds 2	3 to 49 with	WNV pro	tease
Comp.	Ligation type	Ligation Description	Interacti on distance (Å)	aa	Docking/Ligation Energy
29	cation-π	NH⁺ of the amino acid ring with the triazole ring of the molecule	6,13	His <sup>51</sup>	Energy: -3,991
29	cation-π	NH⁺ of the amino acid ring with the triazole ring of the molecule	3,81	His <sup>51</sup>	
29	π-π stacking	Amino acid ring with the phenyl ring of the molecule	5,04	His <sup>51</sup>	
29	π-π stacking	Amino acid ring with the eugenol ring of the molecule	3,96	His <sup>51</sup>	
30	Hydrogen Bond	NH <sup>+</sup> of the amino acid with the OF₃ of the phenyl ring of the molecule	1,96	Gly <sup>133</sup>	
30	Hydrogen Bond	NH <sub>2</sub> of the amino acid with the OCH <sub>3</sub> of the molecule	2,08	Asn <sup>84</sup>	and
30	cation-π	NH <sup>+</sup> of the amino acid ring with the phenyl ring of the molecule	6,01	His <sup>51</sup>	Energy: -1.459
30	π-π stacking	Amino acid ringwith the phenyl ring of the molecule	4,93	His <sup>51</sup>	
31	π-π stacking	Ring of the amino acid with the eugenol ring of the molecule	5,08	Tyr <sup>161</sup>	Energy: +1,993



Energy: +2,136

32

No chemical interaction predicted

		Table A: Docking of the compounds 2	3 to 49 with	WNV pro	tease
Comp.	Ligation type	Ligation Description	Interacti on distance (Å)	аа	Docking/Ligation Energy
33	Hydrogen Bond	NH <sup>+</sup> of the amino acid with the OCH₃ of the eugenol of the molecule	1,80	lle <sup>155</sup>	A A
33	Halogen Bond	OH of the amino acid with the iodine of the molecule	2,68	Ser <sup>135</sup>	Contractor
33	π-π stacking	Ring of the amino acid with the phenyl ring of the molecule	3,80	Tyr <sup>161</sup>	Energy: -1,473
34	Hydrogen Bond	NH2 of the amino acid with the oxygen of the carbonic chain of the molecule	1,84	Asn <sup>84</sup>	Energy: +1,863
35	cation-π	NH <sup>+</sup> of the amino acid ring with the triazole ring of the molecule	5,88	His <sup>51</sup>	
35	π-π stacking	Amino acid ring with the triazole ring of the molecule	5,04	His <sup>51</sup>	Softer
35	π-π stacking	Amino acid ring with the phenyl ring of the molecule	4,22	Tyr <sup>161</sup>	A A T
35	Halogen Bond	OH of the amino acid with Bromo of the molecule	2,10	Ser <sup>135</sup>	Energy: -2 343
35	Halogen Bond	NH <sup>+</sup> do of the amino acid with Bromo of the molecule	3,25	Thr <sup>134</sup>	21101891 21010
36	Hydrogen Bond	NH <sup>+</sup> of the amino acid with the nitrogen of triazole ring of the molecule	2,70	Gly <sup>153</sup>	1 - 1 OKORA
36	π-π stacking	Amino acid ringwith the phenyl ring of the molecule	4,30	Tyr <sup>161</sup>	AN CONTRACT
36	Halogen Bond	NH <sup>+</sup> of the amino acid with Bromo of the molecule	3,19	Gly <sup>133</sup>	the states
36	Halogen Bond	NH <sup>+</sup> of the amino acid with Bromo of the molecule	3,01	Thr <sup>134</sup>	Energy: +1.825
36	Halogen Bond	OH of the amino acid with Bromo of the molecule	2,56	Ser <sup>135</sup>	2

		Ligation			
Comp.	Ligation type	Description	Interacti on distance (Å)	аа	Docking/Ligation Energy
37	cation-π	NH₃⁺ do of the amino acid with the eugenol ring of the molecule	5,31	Lys <sup>54</sup>	Energy: +2,012
38	cation-π	NH₃⁺ of the amino acid with the eugenol ring of the molecule	4,79	Lys <sup>54</sup>	Energy: +1,608
39	Hydrogen Bond	OH of the amino acid with the OCH₃ of the eugenol of the molecule	2,32	Thr <sup>132</sup>	Q Str
39	cation-π	NH <sup>+</sup> of the amino acid ring with the triazole ring of the molecule	3,82	His <sup>51</sup>	A A A A
39	π-π stacking	Amino acid ring with the triazole ring of the molecule	3,51	His <sup>51</sup>	Energy: -2,863
40	Hydrogen Bond	NH <sup>+</sup> of the amino acid with the OCH₃ of the eugenol of the molecule	2,77	His <sup>51</sup>	Energy: +1,347
41	Hydrogen Bond	NH <sup>+</sup> of the amino acid with the oxigênio da cadeia carbônica of the molecule	2,48	Gly <sup>133</sup>	No.
41	Hydrogen Bond	OH of the amino acid with the OCH₃ of the eugenol of the molecule	2,48	Thr <sup>132</sup>	Energy: -2,436
42	Hydrogen Bond	$O^{-}$ of the amino acid with the NO <sub>2</sub> H <sub>2</sub> of the molecule	2,00	Asp <sup>12</sup> 9	. ANA

Table A: Docking of the compounds 23 to 49 with WNV protease						
Comp.	Ligation type	Ligation Description	Interacti on distance (Å)	aa	Docking/Ligation Energy	
42	Hydrogen Bond	$O^{-}$ of the amino acid with the $NO_2H_2$ of the molecule	1,79	Asp <sup>12</sup> 9	Energy: +0,463	
42	cation-π	NH⁺ of the amino acid ring with the triazole ring of the molecule	4,49	His <sup>51</sup>		
42	π-π stacking	Amino acid ringwith the triazole ring of the molecule	3,96	His <sup>51</sup>		
43	Hydrogen Bond	NH <sup>+</sup> of the amino acid with the nitrogen of triazole ring of the molecule	2,26	Gly <sup>133</sup>	A A	
43	cation-π	NH⁺ of the amino acid ring with the triazole ring of the molecule	6,25	His <sup>51</sup>	Chiller Chiller	
43	π-π stacking	Amino acid ringwith the triazole ring of the molecule	5,15	His <sup>51</sup>	Energy: +0,304	
44	Hydrogen Bond	NH⁺ of the amino acid with the OF₃ of the molecule	2,07	Gly <sup>133</sup>		
44	Hydrogen Bond	NH <sub>2</sub> of the amino acid with thexigênio da cadeia carbônica of the molecule	1,73	Asn <sup>84</sup>	Energy: +0,877	
45	Hydrogen Bond	NH⁺ of the amino acid with the nitrogênio da anel triazólico of the molecule	2,62	Gly <sup>133</sup>	Energy: +0,392	
46	Hydrogen Bond	NH⁺ of the amino acid with the oxygen of the carbonic chain of the molecule	2,63	Gly <sup>133</sup>	Energy: +2 811	

	Table A: Docking of the compounds 23 to 49 with WNV protease						
Comp.	Ligation type	Description	Interacti on distance (Å)	аа	Docking/Ligation Energy		
47	Hydrogen Bond	NH2 of the amino acid with the oxygen of the carbonic chain of the molecule	2,03	Asn <sup>84</sup>	- Store		
47	π-π stacking	Amino acid ring with the triazole ring of the molecule	3,64	His <sup>51</sup>	Energy: -3,613		
48	cation-π	NH <sup>+</sup> of the amino acid ring with the triazole ring of the molecule	5,26	His <sup>51</sup>	Contraction of the second		
48	Halogen Bond	OH of the amino acid with Bromo of the molecule	2,13	Ser <sup>135</sup>	Energy: +0,947		
49	π-π stacking	Amino acid ring with the phenyl ring of the molecule	4,11	Tyr <sup>161</sup>	8 - 2 B		
49	Halogen Bond	OH of the amino acid with Bromo of the molecule	2,49	Ser <sup>135</sup>	1 ALAN		
49	Halogen Bond	NH <sup>+</sup> of the amino acid with Bromo of the molecule	3,41	Ser <sup>135</sup>	Energy: +0,969		

## SELECTED IR AND NMR SPECTRA



**Fig. A.** IR spectrum (ATR) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-benzyl-*1H*-1,2,3-triazole (**23**).







**Fig. D.** IR spectrum (ATR) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-fluorobenzyl)-*1H*-1,2,3-triazole (**24**).



**Fig. E.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-fluorobenzyl)-*1H*-1,2,3-triazole (**24**).



**Fig. F.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-fluorobenzyl)-*1H*-1,2,3-triazole (**24**).



**Fig. G.** IR spectrum (ATR) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-chlorobenzyl)-*1H*-1,2,3-triazole (**25**).



**Fig. H.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-chlorobenzyl)-*1H*-1,2,3-triazole (**25**).



**Fig. I.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-chlorobenzyl)-*1H*-1,2,3-triazole (**25**).



**Fig. J.** IR spectrum (ATR) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-bromobenzyl)-*1H*-1,2,3-triazole (**26**).



**Fig. K.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-bromobenzyl)-*1H*-1,2,3-triazole (**26**).



**Fig. L.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-bromobenzyl)-*1H*-1,2,3-triazole (**26**).



**Fig. M.** IR spectrum (ATR) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-iodobenzyl)-*1H*-1,2,3-triazole (**27**).







**Fig. P.** IR spectrum (ATR) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-nitrobenzyl)-*1H*-1,2,3-triazole (**28**).



**Fig. Q.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-nitrobenzyl)-*1H*-1,2,3-triazole (**28**).







**Fig. S.** IR spectrum (ATR) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-methoxybenzyl)-*1H*-1,2,3-triazole (**29**).



**Fig. T.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-methoxybenzyl)-*1H*-1,2,3-triazole (**29**).



**Fig. V.** IR spectrum (ATR) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-(trifluoromethoxy)benzyl)-*1H*-1,2,3-triazole (**30**).





**Fig. W.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-(trifluoromethoxy)benzyl)-*1H*-1,2,3-triazole (**30**).



**Fig. Y.** IR spectrum (ATR) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-(trifluoromethyl)benzyl)-*1H*-1,2,3-triazole (**31**).



**Fig. Z.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-(trifluoromethyl)benzyl)-*1H*-1,2,3-triazole (**31**).



**Fig. AA.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-(trifluoromethyl)benzyl)-*1H*-1,2,3-triazole (**31**).



**Fig. AB.** IR spectrum (ATR) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(3,4-difluorobenzyl)-*1H*-1,2,3-triazole (**32**).



**Fig. AC.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(3,4-difluorobenzyl)-*1H*-1,2,3-triazole (**32**).



**Fig. AD.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(3,4-difluorobenzyl)-*1H*-1,2,3-triazole (**32**).



**Fig. AE.** IR spectrum (ATR) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(2,5-dichlorobenzyl)-*1H*-1,2,3-triazole (**33**).



**Fig. AF.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(2,5-dichlorobenzyl)-*1H*-1,2,3-triazole (**33**).



**Fig. AG.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(2,5-dichlorobenzyl)-*1H*-1,2,3-triazole (**33**).



**Fig. AH.** IR spectrum (ATR) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-methylbenzyl)-*1H*-1,2,3-triazole (**34**).



**Fig. AI.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-methylbenzyl)-*1H*-1,2,3-triazole (**34**).



**Fig. AJ.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(4-methylbenzyl)-*1H*-1,2,3-triazole (**34**).



**Fig. AK.** IR spectrum (ATR) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(2-bromobenzyl)-*1H*-1,2,3-triazole (**35**).



**Fig. AL.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(2-bromobenzyl)-*1H*-1,2,3-triazole (**35**).



**Fig. AM.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(2-bromobenzyl)-*1H*-1,2,3-triazole (**35**).



**Fig. AN.** IR spectrum (ATR) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(3-bromobenzyl)-*1H*-1,2,3-triazole (**36**).



**Fig. AO.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(3-bromobenzyl)-*1H*-1,2,3-triazole (**36**).



**Fig. AP.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 4-((4-allyl-2-methoxyphenoxy)methyl)-1-(3-bromobenzyl)-*1H*-1,2,3-triazole (**36**).



**Fig. AQ.** IR spectrum (ATR) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-benzyl-*1H*-1,2,3-triazole (**37**).







**Fig. AT.** IR spectrum (ATR) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-fluorobenzyl)-*1H*-1,2,3-triazole (**38**).



**Fig. AU.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-fluorobenzyl)-*1H*-1,2,3-triazole (**38**).



**Fig. AV.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-fluorobenzyl)-*1H*-1,2,3-triazole (**38**).



**Fig. AX.** IR spectrum (ATR) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-chlorobenzyl)-*1H*-1,2,3-triazole (**39**).



**Fig. AW.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-chlorobenzyl)-*1H*-1,2,3-triazole (**39**).


**Fig. AZ.** IR spectrum (ATR) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-bromobenzyl)-*1H*-1,2,3-triazole (**40**).



**Fig. BB.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-bromobenzyl)-*1H*-1,2,3-triazole (**40**).



**Fig. BC.** IR spectrum (ATR) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-iodobenzyl)-*1H*-1,2,3-triazole (**41**).



methoxyphenoxy)propyl)-1-(4-iodobenzyl)-1H-1,2,3-triazole (41).



**Fig. BF.** IR spectrum (ATR) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-nitrobenzyl)-*1H*-1,2,3-triazole (**42**).



methoxyphenoxy)propyl)-1-(4-nitrobenzyl)-1H-1,2,3-triazole (42).



**Fig. BI.** IR spectrum (ATR) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-methoxybenzyl)-*1H*-1,2,3-triazole (**43**).



**Fig. BJ.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-methoxybenzyl)-*1H*-1,2,3-triazole (**43**).



**Fig. BL.** IR spectrum (ATR) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-(trifluoromethoxy)benzyl)-*1H*-1,2,3-triazole (**44**).











**Fig. BO.** IR spectrum (ATR) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-(trifluoromethyl)benzyl)-*1H*-1,2,3-triazole (**45**).



methoxyphenoxy)propyl)-1-(4-(trifluoromethyl)benzyl)-*1H*-1,2,3-triazole (**45**).



**Fig. BQ.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-(trifluoromethyl)benzyl)-*1H*-1,2,3-triazole (**45**).



**Fig. BR.** IR spectrum (ATR) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(3,4-difluorobenzyl)-*1H*-1,2,3-triazole (**46**).



**Fig. BS.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(3,4-difluorobenzyl)-*1H*-1,2,3-triazole (**46**).



**Fig. BT.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(3,4-difluorobenzyl)-*1H*-1,2,3-triazole (**46**).



**Fig. BU.** IR spectrum (ATR) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-methylbenzyl)-*1H*-1,2,3-triazole (**47**).



**Fig. BV.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-methylbenzyl)-*1H*-1,2,3-triazole (**47**).



**Fig. BW.** IR spectrum (ATR) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(2-bromobenzyl)-*1H*-1,2,3-triazole (**48**).



**Fig. BZ.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(2-bromobenzyl)-*1H*-1,2,3-triazole (**48**).



**Fig. CA.** IR spectrum (ATR) of 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(3-bromobenzyl)-*1H*-1,2,3-triazole (**49**).









**Fig. CD.** IR spectrum (ATR) of 2,2-*bis*((1-(4-bromobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**51**).



**Fig. CE.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 2,2-bis((1-(4-bromobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1H-indene-1,3(2H)-dione (**51**).



Fig. CF. <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 2,2-bis((1-(4-bromobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1H-indene-1,3(2H)-dione (51).



**Fig. CG.** IR spectrum (ATR) of 2,2-*bis*((1-(3-bromobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**52**).



**Fig. CH.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 2,2-*bis*((1-(3-bromobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**52**).



**Fig. CI.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 2,2-*bis*((1-(3-bromobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**52**).



**Fig. CJ.** IR spectrum (ATR) of 2,2-*bis*((1-(2-bromobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**53**).



Fig. CK. <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 2,2-bis((1-(2-bromobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1H-indene-1,3(2H)-dione (53).



**Fig. CL.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 2,2-*bis*((1-(2-bromobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**53**).



**Fig. CM.** IR spectrum (ATR) of 2,2-*bis*((1-(4-chlorobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**54**).



**Fig. CN.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 2,2-*bis*((1-(4-chlorobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**54**).



Fig. CO. <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 2,2-bis((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1H-indene-1,3(2H)-dione (54).



**Fig. CP.** IR spectrum (ATR) of 2,2-*bis*((1-(4-fluorobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**55**).



**Fig. CQ.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 2,2-*bis*((1-(4-fluorobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**55**).



**Fig. CR.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 2,2-*bis*((1-(4-fluorobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**55**).



**Fig. CS.** IR spectrum (ATR) of 2,2-*bis*((1-(4-methoxybenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**56**).



Fig. CT. <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 2,2-*bis*((1-(4-methoxybenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**56**).



**Fig. CU.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 2,2-*bis*((1-(4-methoxybenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**56**).



**Fig. CV.** IR spectrum (ATR) of 2,2-*bis*((1-(4-(trifluoromethoxy)benzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**57**).



**Fig. CX.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 2,2-*bis*((1-(4-(trifluoromethoxy)benzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**57**).



**Fig. CW.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 2,2-*bis*((1-(4-(trifluoromethoxy)benzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**57**).



**Fig. CY.** IR spectrum (ATR) of 2,2-*bis*((1-(4-nitrobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**58**).



**Fig. CZ.** <sup>1</sup>H NMR spectrum (300 MHz, DMSO-*d*<sub>6</sub>) of 2,2-*bis*((1-(4-nitrobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**58**).



Fig. DA. <sup>13</sup>C NMR spectrum (75 MHz, DMSO- $d_6$ ) of 2,2-*bis*((1-(4-nitrobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**58**).



**Fig. DB.** IR spectrum (ATR) of 2,2-*bis*((1-(2,4-difluorobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**59**).



**Fig. DC.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 2,2-*bis*((1-(2,4-difluorobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**59**).



**Fig. DD.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 2,2-*bis*((1-(2,4-difluorobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**59**).



**Fig. DE.** IR spectrum (ATR) of 2,2-*bis*((1-(4-iodobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**60**).



**Fig. DF.** <sup>1</sup>H NMR spectrum (300 MHz, DMSO-*d*<sub>6</sub>) of 2,2-*bis*((1-(4-iodobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**60**).



**Fig. DG.** <sup>13</sup>C NMR spectrum (75 MHz, DMSO-*d*<sub>6</sub>) of 2,2-*bis*((1-(4-iodobenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**60**).



**Fig. DH.** IR spectrum (ATR) of 2,2-*bis*((1-(2-benzyl-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**61**).



**Fig. DI.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 2,2-*bis*((1-(2-benzyl-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**61**).



Fig. DJ. <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 2,2-*bis*((1-(2-benzyl-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**61**).



**Fig. DK.** IR spectrum (ATR) of 2,2-*bis*((1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)methyl)-1H-indene-1,3(2H)-dione (**62**).





**Fig. DM.** <sup>13</sup>C NMR spectrum (75 MHz, CDCl<sub>3</sub>) of 2,2-*bis*((1-(4-(trifluoromethyl)benzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**62**).



**Fig. DN.** IR spectrum (ATR) of 2,2-*bis*((1-(4-methylbenzyl)-1*H*-1,2,3-triazol-4-yl)methyl)-1*H*-indene-1,3(2*H*)-dione (**63**).



**Fig. DO.** <sup>1</sup>H NMR spectrum (300 MHz, CDCl<sub>3</sub>) of 2,2-bis((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1H-indene-1,3(2H)-dione (**63**).

